Posted by Michael Wonder on 28 Sep 2020
Ultomiris (ravulizumab) receives approval in Japan for atypical haemolytic uraemic syndrome in adults and children
25 September 2020 - Ultomiris is the first and only long-acting C5 inhibitor for atypical haemolytic uraemic syndrome, reducing the treatment burden for adults and children with administration every other month.
Alexion Pharmaceuticals today announced that Japan’s Ministry of Health, Labour and Welfare approved Ultomiris (ravulizumab) for adults and children living with atypical haemolytic uraemic syndrome.
The approval is based on data from two on-going, global, single-arm open-label studies of Ultomiris – one in adults and one in children, referred to as paediatrics in the study.
